臨床外科68巻8号

2013年08月発行

特集 外科医のための癌免疫療法―基礎と臨床 基礎編

がん免疫療法の臨床への展望

著者： 平家勇司¹

所属機関： ¹国立がん研究センター中央病院

ページ範囲：P.894 - P.898

【ポイント】

◆抗CTLA-4抗体や抗PD-1抗体などの，免疫抑制解除抗体が注目を集めている．抗PD-1抗体は，悪性黒色腫だけでなく，腎細胞がん，非小細胞肺がんに対しても，高い抗腫瘍効果が期待されている．

参考文献

1）Topalian SL, Hodi FS, Brahmer JR, et al：Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366：2443-2454, 2012

2）Pardoll DM：The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12：252-264, 2012

3）Hodi FS, O'Day SJ, McDermott DF, et al：Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363：711-723, 2010

4）Brahmer JR, Drake CG, Wollner I, et al：Phase I study of single-agent anti-programmed death-1（MDX-1106）in refractory solid tumors：safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28：3167-3175, 2010

5）Wolchok JD, Hoos A, O'Day S, et al：Guidelines for the evaluation of immune therapy activity in solid tumors：immune-related response criteria. Clin Cancer Res 15：7412-7420, 2009

6）Robert C, Thomas L, Bondarenko I, et al：Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364：2517-2526, 2011

7）Lynch TJ, Bondarenko I, Luft A, et al：Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer：results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30：2046-2054, 2012

8）Reck M, Bondarenko I, Luft A, et al：Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer：results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24：75-83, 2013

9）Wolchok JD, Kluger H, Callahan MK, et al：Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med, 2013〔Epub 2013/06/04〕

10）Brahmer JR, Tykodi SS, Chow LQ, et al：Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366：2455-2465, 2012

11）Kantoff PW, Higano CS, Shore ND, et al：Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363：411-422, 2010

12）Davila ML, Brentjens R, Wang X, et al：How do CARs work?：Early insights from recent clinical studies targeting CD19. Oncoimmunology 1：1577-1583, 2012

13）Grupp SA, Kalos M, Barrett D, et al：Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368：1509-1518, 2013

14）Porter DL, Levine BL, Kalos M, et al：Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365：725-733, 2011

15）Brentjens RJ, Davila ML, Riviere I, et al：CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5：177ra38, 2013

16）Lipowska-Bhalla G, Gilham DE, Hawkins RE, et al：Targeted immunotherapy of cancer with CAR T cells：achievements and challenges. Cancer immunol Immunother 61：953-962, 2012

17）BBC News：Six taken ill after drug trials,（15 March 2006）［http://news.bbc.co.uk/2/hi/uk_news/england/london/4807042.stm］

18）岩崎　甫，三木修治，納田　茂，他：製薬会社はどう考えているのか？　教訓をどう生かすのか？　臨床薬理39：115S-116S, 2008